Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian Patients With Essential Hypertension

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 406 participants.

Also called NCT05880056

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 406 participants (planned count) (from the registry)
Sponsor
Genuine Research Center, Egypt (from the registry)
Registry
  • NCT NCT05880056
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05880056. Allocation not applicable; no masking; primary purpose treatment. Start 2024-08-08 (actual); primary completion 2025-04-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian Patients With Essential Hypertension
Acronym
BETTER
Condition
Essential Hypertension
Intervention (Drug)
Nerkardou (5 mg) & (10 mg)
Lead sponsor
Genuine Research Center, Egypt (class: industry)
Collaborator
Nerhadou International for pharmaceutical & Nutraceutical, Egypt (class: not stated)

Record details

Record id
cardio:ct-nct05880056
Content hash
705a5ee9f6aa85cf471049f33f6acf99414efb67bf1426103cb83eaea4e61a50